Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Musculoskelet Neuronal Interact ; 15(2): 177-85, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26032210

ABSTRACT

OBJECTIVE: Both depression and use of antidepressants have been negatively associated with bone mineral density (BMD) but mainly in studies among postmenopausal women. Therefore, the aim of this study was to investigate these relationships in men. METHODS: Between 2006 and 2011, 928 men (aged 24-98 years) from the Geelong Osteoporosis Study completed a comprehensive questionnaire, clinical measurements and had BMD assessments at the forearm, spine, total hip and total body. Major depressive disorder (MDD) was identified using a structured clinical interview (SCID-I/NP). The cross-sectional associations between BMD and both MDD and antidepressant use were analyzed using multivariable linear regression. RESULTS: Of the study population, 84 (9.1%) men had a single MDD episode, 50 (5.4%) had recurrent episodes and 65 (7.0%) were using antidepressants at the time of assessment. Following adjustments, recurrent MDD was associated with lower BMD at the forearm and total body (-6.5%, P=0.033 and -2.5%, P=0.033, respectively compared to men with no history of MDD), while single MDD episodes were associated with higher BMD at the total hip (+3.4%, P=0.030). Antidepressant use was associated with lower BMD only in lower-weight men (<75-110 kg depending on bone site). CONCLUSIONS: Both depression and use of antidepressants should be taken into account as possible risk factors for osteoporosis in men.


Subject(s)
Antidepressive Agents/adverse effects , Bone Density/drug effects , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/pathology , Adult , Aged , Antidepressive Agents/therapeutic use , Body Weight , Cross-Sectional Studies , Forearm/pathology , Humans , Male , Middle Aged , Osteoporosis/chemically induced , Osteoporosis/epidemiology , Recurrence , Risk Factors , Selective Serotonin Reuptake Inhibitors/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...